Arrowhead Pharmaceuticals, Inc.
ARWRArrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Drugs in Pipeline
20
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
2 upcoming, 2 past
How ARWR's past catalysts played out
Plozasiran Injection
Severe Hypertriglyceridemia
zodasiran Injection
Homozygous Familial Hypercholesterolemia
Plozasiran
Familial Chylomicronemia
ARO-MMP7 Inhalation Solution
Idiopathic Pulmonary Fibrosis
ARO-APOC3
Mixed Dyslipidemia
ARO-MAPT-SC
Alzheimer Disease
ARO-INHBE
Obesity
ARO-HSD Injection
Non-alcoholic Steatohepatitis
ARO-AAT
Alpha 1-Antitrypsin Deficiency
ARO-C3
C3 Glomerulopathy
ARO-ALK7
Obesity
ARO-HBV
Hepatitis B
ARO-RAGE
Asthma
Fazisiran Injection
Alpha 1-Antitrypsin Deficiency
ARO-ANG3
Mixed Dyslipidemia
ARO-ANG 3 Injection
Homozygous Familial Hypercholesterolemia
ARO-DIMERPA
Hyperlipidemia; Mixed
ARO-DUX4 for Injection
Facio-Scapulo-Humeral Dystrophy
ARO-DM1 Intravenous (IV) Infusion
Myotonic Dystrophy 1
ARO-CFB
IgA Nephropathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Plozasiran Injection | Phase 3 | Severe Hypertriglyceridemia | - | - |
zodasiran Injection | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Plozasiran | Phase 3 | Familial Chylomicronemia | - | - |
ARO-MMP7 Inhalation Solution | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
ARO-APOC3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-MAPT-SC | Phase 2 | Alzheimer Disease | - | - |
ARO-INHBE | Phase 2 | Obesity | - | - |
ARO-HSD Injection | Phase 2 | Non-alcoholic Steatohepatitis | - | - |
ARO-AAT | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-C3 | Phase 2 | C3 Glomerulopathy | - | - |
ARO-ALK7 | Phase 2 | Obesity | - | - |
ARO-HBV | Phase 2 | Hepatitis B | - | - |
ARO-RAGE | Phase 2 | Asthma | - | - |
Fazisiran Injection | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
ARO-ANG3 | Phase 2 | Mixed Dyslipidemia | - | - |
ARO-ANG 3 Injection | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
ARO-DIMERPA | Phase 2 | Hyperlipidemia; Mixed | - | - |
ARO-DUX4 for Injection | Phase 2 | Facio-Scapulo-Humeral Dystrophy | - | - |
ARO-DM1 Intravenous (IV) Infusion | Phase 2 | Myotonic Dystrophy 1 | - | - |
ARO-CFB | Phase 2 | IgA Nephropathy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arrowhead Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 20 drug candidates in Arrowhead Pharmaceuticals, Inc.'s (ARWR) pipeline across Phase 3, Phase 2. Its lead program is Plozasiran Injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arrowhead Pharmaceuticals, Inc.'s next FDA catalyst?→
Arrowhead Pharmaceuticals, Inc.'s (ARWR) next tracked catalyst is a Phase 2 expected February 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARWR biotech catalysts?→
Add ARWR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arrowhead Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.